tiprankstipranks
Viridian Therapeutics reports Q3 EPS ($1.15), consensus ($1.06)
PremiumThe FlyViridian Therapeutics reports Q3 EPS ($1.15), consensus ($1.06)
14d ago
Is VRDN a Buy, Before Earnings?
Premium
Pre-Earnings
Is VRDN a Buy, Before Earnings?
17d ago
Viridian Therapeutics management to meet with Jefferies
Premium
The Fly
Viridian Therapeutics management to meet with Jefferies
1M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
2M ago
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
Premium
The Fly
Viridian Therapeutics price target raised to $44 from $35 at RBC Capital
2M ago
Viridian Therapeutics 10.67M share Secondary priced at $18.75
Premium
The Fly
Viridian Therapeutics 10.67M share Secondary priced at $18.75
3M ago
Viridian TED data adds new overhang to Amgen’s Tepezza growth, says Barclays
PremiumThe FlyViridian TED data adds new overhang to Amgen’s Tepezza growth, says Barclays
3M ago
Viridian poised to take share in TED market, says H.C. Wainwright
Premium
The Fly
Viridian poised to take share in TED market, says H.C. Wainwright
3M ago
Viridian Therapeutics price target raised to $56 from $46 at BTIG
Premium
The Fly
Viridian Therapeutics price target raised to $56 from $46 at BTIG
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100